Dr. Antonis Koromilas graduated from the Aristotle University of Thessaloniki, in Greece, in addition to completing several trainings at Stockholm University, Kyoto University, and McGill University. He focused his research on the role of protein synthesis and immune regulatory pathways involved in the formation of breast cancers and treatments with chemotherapeutic agents.
Why Choosing Breast Cancer?
Breast cancer is not one disease, but rather many diseases often associated with a mortality rate that is still high in spite of significant progress made in therapy development over the past few years. Hence, to fight this cancer, it is necessary to explore more effective treatments that produce fewer side effects. Basic research has been of paramount importance in this area as it led to a better understanding of the origin of breast cancers. Therapies targeting breast cancers may also be relevant for the treatment of other forms of cancer since many forms of cancer share a common origin.
A Scientific Accomplishment You Are Proud of
My lab contributed significantly to understanding the role of the protein synthesis machinery in cells undergoing various forms of environmental stress during the formation of breast cancers. My works also led to a better understanding of the function of the immune system proteins, both in the development of breast cancers and in anti-tumour responses to chemotherapeutic agents.
Field(s) of Research
- Cancer biology
- Etiology (causes)
- Screening, diagnosis or prognosis
- Development of scientific models
1987 – Short-Term Fellowship from the European Molecular Biology Organization (EMBO)
1993 – International award from the American Foundation for AIDS Research (AmFAR)
1997 – Research Scholar award from the Fonds de recherche du Québec – Santé (FRQS)
1998 – Training award from the Canadian Institutes of Health Research (CIHR)
2003 – Fellowship award from the Japanese Society for the Promotion of Science (JSPS)
2010-2011 – Award for Excellence in Basic Research
Projects Funded by the Foundation
2008 – Characterization of elF2a kinases as novel targets of oncogenic signaling in breast tumorigenesis with therapeutic potential
2011 – Mechanisms of anti-tumor activity of Stat1 in ErbB2-positive breast cancers and therapeutic implications